Novel screening assay for antioxidant protection against peroxyl radical-induced loss of protein function

Journal of Pharmaceutical Sciences

Volumn 96, Issue 11, 2007, Pages 2931-2944

  Bertolini, Francesca ^a   Novaroli, Laura ^a   Carrupt, Pierre Alain ^a   Reist, Marianne ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Alkaline phosphatase; Antioxidants; COMT inhibitors; Fluorescence spectroscopy; in vitro models; Kinetics; Multifunctional hits; Oxidation; Peroxyl radicals; Proteins

Indexed keywords

2,2' AZOBIS(2 METHYLPROPIONAMIDINE) DIHYDROCHLORIDE; 4 METHYLUMBELLIFERYL PHOSPHATE; ALKALINE PHOSPHATASE; AMIDINE; ASCORBIC ACID; CAFFEIC ACID; CHLOROGENIC ACID; ENTACAPONE; GLUTATHIONE; HYMECROMONE; MANGIFERIN; MANNITOL; MELATONIN; NITECAPONE; QUERCETIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; TOLCAPONE; TROLOX C; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; DISEASE COURSE; NONHUMAN; PARKINSON DISEASE; PROTEIN FUNCTION;

EID: 36849087430     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20881     Document Type: Article

References (51)

1. Finkel T, Holbrook NJ. 2000. Oxidants, oxidative stress and the biology of ageing. Nature 408:239-247.
2. Sies H. 1993. Strategies of antioxidant defense. Eur J Biochem 215:213-219.
3. Zhu X, Raina AK, Lee H, Casadesus G, Smith MA, Perry G. 2004. Oxidative stress signalling in Alzheimer's disease. Brain Res 1000:32-39.
4. Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, Markesbery WR. 1991. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA 88:10540-10543.
5. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Aksenova M, Gabbita P, Wu JF, Carney JM, Lovell M, Markesbery WR, Butterfield DA. 1995. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 65:2145-2156.
6. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B. 1997. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental lewy body disease. J Neurochem 69:1326-1329.
7. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N. 1996. Oxidative damage in Alzheimer's. Nature 382:120-121.
8. Zhang H-Y, Yang D-P, Tang G-Y. 2006. Multipotent antioxidants: From screening to design. Drug Discov Today 11:749-754.
9. Boschi D, Tron GC, Lazzarato L, Chegaev K, Cena C, Di Stilo A, Giorgis M, Bertinaria M, Fruttero R, Gasco A. 2006. NO-donor phenols: A new class of products endowed with antioxidant and vasodilator properties. J Med Chem 49:2886-2897.
10. Gasco A, Fruttero R, Rolando B. 2005. Focus on recent approaches for the development of new NO-donors. Mini Rev Med Chem 5:217-229.
11. Horvathova K, Chalupa I, Sebova L, Tothova D, Vachalkova A. 2005. Protective effect of quercetin and luteolin in human melanoma HMB-2 cells. Mutat Res 565:105-112.
12. Colic M, Pavelic K. 2000. Molecular mechanisms of anticancer activity of natural dietetic products. J Mol Med 78:333-336.
13. Di Stefano A, Sozio P, Cocco A, Iannitelli A, Santucci E, Costa M, Pecci L, Nasuti C, Cantalamessa F, Pinnen F. 2006. L-dopa- and dopamine-(R)-alpha- lipoic acid conjugates as multifunctional codrugs with antioxidant properties. J Med Chem 49:1486-1493.
14. Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, Youdim MB. 2005. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: In vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 95:68-78.
15. Rodriguez-Franco MI, Fernandez-Bachiller MI, Perez C, Hernandez-Ledesma B, Bartolome B. 2006. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J Med Chem 49:459-462.
16. Youdim MB, Buccafusco JJ. 2005. CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases. J Neural Transm 112:519-537.
17. Mandel S, Grunblatt E, Riederer P, Gerlach M, Levites Y, Youdim MB. 2003. Neuroprotective strategies in Parkinson's disease: An update on progress. CNS Drugs 17:729-762.
18. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. 2004. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5:863-873.
19. Sundell CL, Somers PK, Meng CQ, Hoong LK, Suen K-L, Hill RR, Landers LK, Chapman A, Butteiger D, Jones M, Edwards D, Daugherty A, Wasserman MA, Alexander RW, Medford RM, Saxena U. 2003. AGI-1067: A multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent. J Pharmacol Exp Ther 305:1116-1123.
20. Christiaans JAM, Timmerman H. 1996. Cardiovascular hybrid drugs: Combination of more than one pharmacological property in one single molecule. Eur J Pharm Sci 4:1-22.
21. Kaur IP, Geetha T. 2006. Screening methods for antioxidants-A review. Mini Rev in Med Chem 6:305-312.
22. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn BW, Shaltiel S, Stadtman ER. 1994. Determination of carbonyl content in oxidatively modified proteins. Meth Enzymology 186:464-479.
23. Meucci E, Mordente A, Martorana GE. 1991. Metal-catalyzed oxidation of human serum albumin: Conformational and functional changes. J Biol Chem 266:4692-4699.
24. Hunt JV, Simpson JA, Dean RT. 1988. Hydroperoxide-mediated fragmentation of proteins. Biochem J 250:87-93.
25. Halliwell B. 1996. Oxidative stress, nutrition and health. Experimental strategies for optimization of nutritional antioxidant intake in humans. Free Radical Res 25:57-74.
26. Salvi A, Brühlmann C, Migliavacca E, Carrupt PA, Hostettmann K, Testa B. 2002. Protein protection by antioxidants: Development of a convenient assay and structure-activity relationships of natural polyphenols. Helv Chim Acta 85:867-881.
27. Halliwell B, Evans P, Whiteman M. 1999. Assessment of peroxynitrite scavengers in vitro. Meth Enzymology 301:333-342.
28. Coleman EJ. 1992. Structure and mechanism of alkaline phosphatase. Annu Rev Biophys Biomol Struct 21:441-483.
29. Niki E. 1990. Free radical initiators as source of water- or lipid-soluble peroxyl radicals. Meth Enzymology 186:100-108.
30. Bonifati V, Meco G. 1999. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease. Pharmacol Ther 81:1-36.
31. Orama M, Tilus P, Taskinen J, Lotta T. 1997. Iron(III)-chelating properties of the novel catechol O-methyltransferase inhibitor entacapone in aqueous solution. J Pharm Sci 86:827-831.
32. Marcocci L, Maguire JJ, Packer L. 1994. Nitecapone: A nitric oxide radical scavenger. Biochem Mol Biol Int 34:531-541.
33. Suzuki YJ, Tsuchiya M, Safadi A, Kagan VE, Packer L. 1992. Antioxidant properties of nitecapone (Or-462). Free Rad Biol Med 13:517-525.
34. Pentikäinen MO, Lindstedt KA, Kovanen PT. 1995. Inhibition of the oxidative modification of LDL by nitecapone. Arterioscler Thromb Vasc Biol 15:740-747.
35. Reichling JJ, Kaplan MM. 1988. Clinical use of serum enzymes in liver diseases. Dig Dis Sci 33:1601-1614.
36. Friedman LS, Martin P, Munoz SJ. 1996. Liver function tests and the objective evaluation of the patient with liver disease. In: Zakim D, editors. Hepathology: A Textbook of Liver Disease. Philadelphia: WB Saunders. pp 791-833.
37. Simandan T, Sun J, Dix TA. 1998. Oxidation of DNA bases, deosyribonucleosides and homopolymers by peroxyl radicals. Biochem J 335:233-430.
38. Spiteller G. 2006. Peroxyl radicals: Inductors of neurodegenerative and other inflammatory diseases. Their origin and how they transform choloesterol, phospholipids, plasmalogens, polyunsaturated fatty acids, sugars and proteins into deleterious products. Free Rad Biol Med 41:362-387.
39. Dean RT, Fu S, Stocker R, Davies MJ. 1997. Biochemistry and pathology of radical-mediated protein oxidation. Biochem J 324:1-18.
40. Terao K, Niki E. 1986. Damage to biological tissues induced by radical initiator 2, 2′-azobis(2-amidinopropane) dihydrochloride and its inhibition by chain-breaking antioxidants. Free Rad Biol Med 2:193-201.
41. van Acker SABE, van den Berg DJ, Tromp MNJL, Griffioen DH, van Bennekom WP, van der Vijgh WJF, Bast A. 1996. Structural aspects of antioxidant activity of flavonoids. Free Rad Biol Med 20:331-342.
42. Stephen S, Chang X, Bin-Hua J, Beth S, Hillar K, Gabriel KH, Xianglin S. 2003. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun 309:1017-1026.
43. Fauconneau B, Waffo-Teguo P, Huguet F, Barrier L, Decendit A, Merillon J-M. 1997. Comparative study of radical scavenger and antioxidant properties of phenolic compounds from vitis vinifera cell cultures using in vitro tests. Life Sciences 61:2103-2110.
44. Zou J, Huang Y, Chen Q, Wei E, Cao K, Wu JM. 2000. Effects of resveratrol on oxidative modification of human low density lipoprotein. Chim Med J 113:99-102.
45. Kocha T, Yamaguchi M, Ohtaki H, Fukuda T, Aoyagi T. 1997. Hydrogen peroxide-mediated degradation of protein: Different oxidation modes of copper- and iron-dependent hydroxyl radicals on the degradation of albumin. Biochim Biophys Acta 1337:319-326.
46. Regoli F, Winston GW. 1999. Quantification of total oxidant scavenging capacity of antioxidants for peroxynitrite, peroxyl radicals, and hidroxyl radicals. Toxicol Appl Pharmacol 156:96-105.
47. Mayo JC, Tan DX, Sainz RM, Natarajan M, Lopez-Burillo S, Reiter RJ. 2003. Protection against oxidative protein damage induced by metal-catalyzed reaction or alkylperoxyl radicals: Comparative effects of melatonin and other antioxidants. Biochim Biophys Acta 1620:139-150.
48. Mayo JC, Tan DX, Sainz RM, Lopez-Burillo S, Reiter RJ. 2003. Oxidative damage to catalase induced by peroxyl radicals: Functional protection by melatonin and other antioxidants. Free Rad Res 5:543-553.
49. Youdim MBH, Buccafusco JJ. 2005. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Pharmacol Sci 26:27-35.
50. Novaroli L, Bouchard G, Reist M, Rolando B, Fruttero R, Gasco A, Carrupt PA. 2006. The lipophilicity behavior of three catechol-O-methyltransferase (COMT) inhibitors and simple analogues. Helv Chim Acta 89:144-152.
51. Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT. 2003. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: A comparative study in the rat. J Pharmacol Exp Ther 304:498-506.